Adagrasib for Healthy Subjects

This trial tests a new treatment called Adagrasib, a potential cancer drug, to assess its behavior in the body and its safety and tolerability. The study focuses on healthy participants of Japanese descent to understand how the drug works in this specific group. Healthy adults with no major health issues and both parents of Japanese ethnicity might be suitable candidates for this trial. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

Research has shown that Adagrasib has been tested in various situations and generally has a manageable safety profile. Previous studies found no new safety issues. Some patients experienced side effects like nausea, tiredness, and vomiting, which typically led to temporary treatment breaks rather than complete discontinuation.

A real-world review of side effects identified some serious reactions, such as lung inflammation and pneumonia, though these were rare. Overall, the treatment was well-tolerated, with most side effects being manageable.

Adagrasib is unique because it targets a specific mutation in the KRAS gene, which is often involved in the growth of cancer cells. Unlike traditional chemotherapy that affects both healthy and cancerous cells, Adagrasib is designed to specifically inhibit the mutant KRAS protein, potentially leading to fewer side effects and more effective cancer control. Researchers are excited about Adagrasib because it represents a targeted approach, which could provide better outcomes for patients with cancers driven by this mutation.

Research has shown that adagrasib may help treat cancers with the KRAS G12C mutation. In one study, 35.1% of patients responded positively to the treatment. Another study found that 42.9% of patients responded well, with benefits lasting about 8.5 months. In both studies, patients lived longer without their disease worsening. This evidence suggests that adagrasib could be effective for conditions linked to the KRAS G12C mutation.⁶⁷⁸⁹¹⁰